Prima Biomed Ltd., of Sydney, reported interim data for its TACTI-mel (Two ACTive Immunotherapeutics in melanoma) trial, with the database safety and monitoring board confirming that IMP321 is safe and well-tolerated at the first dose level when used in combination with a PD-1-blocking antibody, and dose-escalation can continue as planned.